Galderma’s Sales Surge 9.2% on Rising Demand for Skincare and Injectable Aesthetics - Global Cosmetics News

Posted by Global Cosmetics News | Oct 28, 2024 | Europe, Finance |

THE WHAT? Swiss skincare giant Galderma, known for brands like Cetaphil, recorded a 9.2% year-on-year sales growth, totaling $3.26 billion for the first nine months of 2024. Driven by robust demand for skincare and injectables, the growth was bolstered by strong performances in Europe, China, and Latin America.

THE DETAILS Galderma’s International reporting area, covering all countries outside the U.S., drove 59% of its group sales, with over 10% growth in Injectable Aesthetics and Dermatological Skincare segments. Shares have surged by over 47% since its IPO in March, reflecting investor confidence in the company’s growth trajectory. CEO Flemming Ornskov highlighted rapid growth in China and the Asia-Pacific region, with the UK also showing significant sales gains. Galderma maintains its 2024 sales forecast of 8.8%-9.5% growth, signaling a steady expansion path while withholding specific guidance for 2025.

THE WHY? Galderma’s strong performance underscores the global demand for premium skincare and aesthetic solutions, particularly in emerging markets like China and Latin America. With increased consumer interest in dermatological care and injectable aesthetics, the brand’s international strategy is paying dividends. Positioned as a growth-oriented company, Galderma continues to capitalize on evolving skincare trends, reinforcing its status as a global leader and maintaining its growth momentum well into 2024.

Share:

Rate: